Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May;10(Suppl 13):S1516-S1533.
doi: 10.21037/jtd.2017.12.52.

Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients

Jordi Remon  1 , Laura Mezquita  2 , Jesús Corral  3 , Noelia Vilariño  4 , Noemi Reguart  4
Affiliations
Review

Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients

Jordi Remon et al. J Thorac Dis. 2018 May.

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized treatment landscape among non-small cell lung cancer (NSCLC) patients in first- and second-line setting, and may become soon new treatment options in other thoracic malignancies such as small cell lung cancer (SCLC) or mesothelioma. The use of these drugs has indubitably changed the toxicity profile the oncologists are familiar with, and new spectra of immune-related adverse events are being reported with the widespread use of immunotherapies in solid tumors. Clinical management and understanding of immune-related adverse events is new and complex but expertise is still limited. In this review, we are summarizing the incidence and management of main side effects related to ICIs focusing on NSCLC patients.

Keywords: Immune-related; adverse events; non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Spectrum of toxicity of ICIs (from Champiat et al. with permission of Annals of Oncology). ICI, immune checkpoint inhibitor.
Figure 2
Figure 2
Median time to onset immune-related adverse events for different toxicities with anti-PD-1 (nivolumab) in NSCLC patients. Circles represent medians; bars signify ranges. Inf. reaction, infusion reaction or hypersensitivity; NSCLC, non-small cell lung cancer.
Figure 3
Figure 3
The five pillars of immunotherapy toxicity management (from Champiat et al. with permission of Ann of Oncology).
See this image and copyright information in PMC

References

    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Carbone DP, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 2017;376:2415-26. 10.1056/NEJMoa1613493 - DOI - PMC - PubMed
    1. Peters S, Gettinger S, Johnson ML, et al. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017;35:2781-9. 10.1200/JCO.2016.71.9476 - DOI - PMC - PubMed
    1. Jerusalem G, Chen F, Spigel D, et al. JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC. J Thorac Oncol 2017;12:S252 10.1016/j.jtho.2016.11.240 - DOI
    1. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18:31-41. 10.1016/S1470-2045(16)30624-6 - DOI - PMC - PubMed

LinkOut - more resources